{
    "root": "4b7cbcd3-7192-43cf-bd16-98bc8ed95645",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lo Loestrin Fe",
    "value": "20250307",
    "ingredients": [],
    "indications": "lo loestrin® fe indicated women prevent pregnancy [ ( 14 ) ] . efficacy lo loestrin fe women body mass index ( bmi ) > 35 kg/m2 evaluated .",
    "contraindications": "take one tablet mouth time every day 28 days ( 2.1 ) take tablets order directed blister pack ( 2.1 )",
    "warningsAndPrecautions": "lo loestrin® fe ( norethindrone acetate ethinyl estradiol tablets , ethinyl estradiol tablets ferrous fumarate tablets ) available blister cards ( dispensers ) containing 28 tablets : ndc 0430-0420-14 cartons 5 blister cards ( dispensers ) ndc 0430-0420-60 cartons 30 blister cards ( dispensers ) blister card ( 28 tablets ) contains following order : 24 blue , round tablets ( active ) imprinted “ wc ” one side “ 421 ” containing 1 mg norethindrone 10 mcg ethinyl estradiol 2 white , hexagonal tablets ( active ) imprinted “ wc ” one side “ 422 ” containing 10 mcg ethinyl estradiol 2 brown , round tablets ( non-hormonal placebo ) imprinted “ wc ” one side “ 624 ” containing 75 mg ferrous fumarate",
    "adverseReactions": "lo loestrin fe contraindicated females known develop following conditions : high risk arterial venous thrombotic diseases . examples include women known : • smoke , age 35 [ boxed warning ( 5.1 ) ] • deep vein thrombosis pulmonary embolism , past [ ( 5.1 ) ] • cerebrovascular disease [ ( 5.1 ) ] • coronary artery disease [ ( 5.1 ) ] • thrombogenic valvular thrombogenic rhythm diseases heart ( example , subacute bacterial endocarditis valvular disease , atrial fibrillation ) [ ( 5.1 ) ] • inherited acquired hypercoagulopathies [ ( 5.1 ) ] • uncontrolled hypertension [ ( 5.5 ) ] • diabetes mellitus vascular disease [ ( 5.7 ) ] • headaches focal neurological symptoms migraine headaches without aura age 35 [ ( 5.8 ) ] current diagnosis , history , breast cancer , may hormone-sensitive [ ( 5.2 ) ] liver tumors , benign malignant , liver disease [ ( 5.3 ) ] undiagnosed abnormal uterine bleeding [ ( 5.9 ) ] hepatitis c combinations containing ombitasvir/paritaprevir/ritonavir , without dasabuvir , due potential alt elevations [ ( 5.4 ) ] .",
    "indications_original": "Lo Loestrin® Fe is indicated for use by women to prevent pregnancy [\n                     see \n                     \n                        Clinical Studies (14)\n                     \n                     ].  \n                  The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of > 35 kg/m2 has not been evaluated.",
    "contraindications_original": "Take one tablet by mouth at the same time every day for 28 days ( 2.1 ) Take tablets in the order directed on the blister pack ( 2.1 )",
    "warningsAndPrecautions_original": "Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) is available in blister cards (dispensers) containing 28 tablets: \n                        NDC 0430-0420-14 \n\t\t     \n\t\n\t\t     \n\tCartons of 5 blister cards (dispensers) \n                        NDC 0430-0420-60 \n\t\t     \n\t\n\t\t     \n\tCartons of 30 blister cards (dispensers)  \n                        Each blister card (28 tablets) contains in the following order:\n                        \n                           24 blue, round tablets (active) imprinted with “WC” on one side and “421” on the other and each containing 1 mg norethindrone and 10 mcg ethinyl estradiol\n                           \n                           2 white, hexagonal tablets (active) imprinted with “WC” on one side and “422” on the other and each containing 10 mcg ethinyl estradiol\n                           \n                           2 brown, round tablets (non-hormonal placebo) imprinted with “WC” on one side and “624” on the other and each containing 75 mg ferrous fumarate",
    "adverseReactions_original": "Lo Loestrin Fe is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:• Smoke, if over age 35 [see \n                        \n                           Boxed Warning\n                        \n                         and \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        • Have deep vein thrombosis or pulmonary embolism, now or in the past [see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        • Have cerebrovascular disease [see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        • Have coronary artery disease [see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        • Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        • Have inherited or acquired hypercoagulopathies [see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        • Have uncontrolled hypertension [see \n                        \n                           Warnings and Precautions (5.5)\n                        \n                        ]\n                        • Have diabetes mellitus with vascular disease [see \n                        \n                           Warnings and Precautions (5.7)\n                        \n                        ]\n                        • Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see \n                        \n                           Warnings and Precautions (5.8)\n                        \n                        ]\n                        \n                     \n                     Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see \n                        \n                           Warnings and Precautions (5.2)\n                        \n                        ]\n                        \n                     \n                     Liver tumors, benign or malignant, or liver disease [see \n                        \n                           Warnings and Precautions (5.3)\n                        \n                        ]\n                        \n                     \n                     Undiagnosed abnormal uterine bleeding [see \n                        \n                           Warnings and Precautions (5.9)\n                        \n                        ]\n                        \n                     \n                     Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see \n                        \n                           Warnings and Precautions (5.4)\n                        \n                        ]."
}